The metastatic lymph node ratio predicts survival in colon cancer - 21/08/11
, Jason Fleming, M.D. b, Thomas Anthony, M.D. a
Corresponding author. Tel.: +1-214-648-9459; fax: +1-214-648-7965.Abstract |
Background |
Lymph node metastases are the most important predictor of survival in non–stage IV colon cancer. Recent studies of gastric cancer have shown a prognostic significance of a lymph node ratio (number of positive nodes divided by total number harvested). Our goal was to determine whether a lymph node ratio (LNR) would predict disease-free survival (DFS) and overall survival (OS) in a tertiary care Veterans Affairs medical center.
Methods |
A retrospective review of a prospectively collected database of colon cancer patients was performed to determine the effect of LNR on DFS and OS. A cohort of 232 patients with non–stage IV colon cancer was eligible for analysis. Survival curves were constructed using the Kaplan-Meier method.
Results |
For all patients, a LNR of .08 was identified as a breakpoint for predicting OS and DFS. Specific analysis of stage III patients revealed that a LNR of .18 was predictive of DFS.
Conclusions |
This study showed the prognostic significance of ratio-based staging for colon cancer and may aid in future staging systems.
El texto completo de este artículo está disponible en PDF.Keywords : Colon cancer, Lymph node ratio, Prognosis, Survival
Esquema
| P.S. and S.D. contributed equally to this work. |
Vol 194 - N° 6
P. 827-832 - décembre 2007 Regresar al número
Artículo precedente
- Management of T2 gallbladder cancer: are practice patterns consistent with national recommendations?
- Byron E. Wright, Chris C. Lee, Douglas M. Iddings, Maihgan Kavanagh, Anton J. Bilchik
- Cancer of unknown primary origin: a decade of experience in a community-based hospital
- Jose M. Pimiento, Desarom Teso, Alpin Malkan, Stanley J. Dudrick, J. Alexander Palesty
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?